Skip to main content
. 2019 May 22;10:327. doi: 10.3389/fendo.2019.00327

Table 1.

Effects of dopamine agonists bromoscriptine and cabergoline on metabolic abnormalities in patients with hyperprolactinemia.

Bromocriptine Cabergoline
Body weight
BMI
Fasting glucose
Fasting insulin
Insulin sensitivity
Insulin resistance
Prevalence of metabolic syndrome

Arrows indicate the increase or the decrees of metabolic parameters.